DSP Healthcare Fund - Growth - Regular Plan

  • Previous Nav

  • Net Change on 25-09-2020

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
S&P BSE Health Care 1.24 17.05 51.51 12.51 1.95 14.67

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Nippon India Pharma Fund-Growth Plan-Growth Jun 05, 2004 51.66 18.09 7.20 2.09 3,652.59
SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH Jul 14, 1999 50.76 10.45 2.40 2.23 1,360.70
UTI Healthcare Fund - Regular Plan - Growth Option Aug 01, 2005 54.48 13.89 4.49 2.81 563.44

Fund Holdings as on 31-August-2020

  • IPCA Laboratories Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Divi's Laboratories Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Aarti Drugs Limited

  • Procter & Gamble Health Limited

  • TREPS / Reverse Repo Investments / Corporate Debt Repo

  • Abbott Laboratories

  • Intuitive Surgical Inc

  • Jubilant Life Sciences Limited

  • Alkem Laboratories Limited

  • Torrent Pharmaceuticals Limited

  • Apollo Hospitals Enterprise Limited

  • Dr. Lal Path Labs Ltd.

  • Syngene International Limited

  • Narayana Hrudayalaya Ltd.

  • Abiomed Inc

  • Max Healthcare Institute Ltd

  • Indoco Remedies Limited

  • ICICI Lombard General Insurance Company Limited

  • Alembic Pharmaceuticals Limited

  • Unichem Laboratories Limited

  • Abbott India Limited

  • Ajanta Pharma Limited

  • Max India Limited

  • Net Receivables/Payables

View More
  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

  • Chemicals

  • Insurance

  • Finance - Investment

View More

Fund Manager

  • Education:B.Com, M Sc Finance, MBA
  • Experience:
  • Basic Details:Aditya has worked across the world, including in the US, EU, Latin America and in India. He started his career working with Glenmark Pharma in 2005 and worked in Brazil and Argentina. He then moved to Lehman Brothers(US) in 2007 and covered US generics companies like Teva, Mylan etc. He then worked with Nomura (UK) in 2008, covering MNC Pharma companies like GSK,Novartis, Sanofi among others, moving to Nomura India in 2011, where he started coverage of Indian Healthcare sector. Aditya joined DSP in 2015. He has an MSc.(Finance), PGDM (MDI,Gurgaon),CIIA (UK),CFA (ICFAI).
  • Funds Managed:
  • DSP Healthcare Fund
  • DSP Healthcare Fund
  • Cash

  • Equity

View More

About DSP Healthcare Fund

Scheme Analysis

DSP Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to DSP Mutual Fund. It was launched on 30-Nov-2018 and currently has an AUM of ₹707.65 crore. DSP Healthcare Fund is benchmarked against S&P BSE Health Care as primary index.

The NAV of DSP Healthcare Fund ended up ₹0.31(1.86%)yesterday to ₹17.204.

Among its top 3 holdings the fund has exposure to IPCA Laboratories Limited, and

The DSP Healthcare Fund is managed by Vinit Sambre and Jay Kothari.

Fund House Contact

Mafatlal Centre, 10th Floor, Nariman Point, Mumbai - 400 021

+91 (22) 66578000
+91 (22) 66578181